Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.11.24	Lilly announces changes on board of directors (EN, Eli Lilly)
18.11.24	Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose (EN, Eli Lilly)
18.11.24	Incyclix Bio And Eli Lilly To Evaluate INX-315, Verzenio, And Fulvestrant In HR+/HER2- Breast Cancer (RTTNews)
17.11.24	Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity (RTTNews)
16.11.24	Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity (EN, Eli Lilly)
15.11.24	Lilly Statement on New 340B Litigation (EN, Eli Lilly)
13.11.24	Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks (EN, Eli Lilly)
05.11.24	Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (EN, Eli Lilly)
01.11.24	Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium (EN, Eli Lilly)
30.10.24	Lilly Cuts FY24 Earnings, Revenue Outlook After Q3 Misses Street; Stock Down In Pre-market - Update (RTTNews)
30.10.24	Eli Lilly And Co. Q3 Earnings Summary (RTTNews)
30.10.24	Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products (EN, Eli Lilly)
29.10.24	Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study (EN, Eli Lilly)
28.10.24	Lilly declares fourth-quarter 2024 dividend (EN, Eli Lilly)
28.10.24	ViaNautis Bio, Lilly Partner For ViaNautis' Drug Delivery Platform PolyNaut (RTTNews)
28.10.24	Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease (EN, Eli Lilly)
22.10.24	Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs (RTTNews)
16.10.24	Lilly confirms date and conference call for third-quarter 2024 financial results announcement (EN, Eli Lilly)
14.10.24	Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges (RTTNews)
14.10.24	Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease (RTTNews)
14.10.24	Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease (EN, Eli Lilly)
08.10.24	Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer (EN, Eli Lilly)
02.10.24	Eli Lilly To Create Indiana Medicine Foundry For Advanced Manufacturing And Drug Development (RTTNews)
02.10.24	Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials (EN, Eli Lilly)
26.09.24	Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab (RTTNews)
25.09.24	Lilly Reports New Long-term Data For Its Atopic Dermatitis Treatment Ebglyss (RTTNews)
25.09.24	New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis (EN, Eli Lilly)
24.09.24	Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla In Japan (RTTNews)
24.09.24	Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease (EN, Eli Lilly)
13.09.24	FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis (EN, Eli Lilly)
12.09.24	Eli Lilly Lifts Manufacturing Investment In Limerick By $1 Bln - Quick Facts (RTTNews)
12.09.24	Lilly expands manufacturing footprint in Ireland with $1.8 billion investment (EN, Eli Lilly)
11.09.24	Lilly's Weekly Efsitora Alfa Insulin Delivers A1C Reduction Consistent With Daily Insulin (RTTNews)
10.09.24	With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes (EN, Eli Lilly)
10.09.24	Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes (EN, Eli Lilly)
09.09.24	Lilly Names Lucas Montarce EVP And CFO With Immediate Effect (RTTNews)
09.09.24	Lilly appoints Lucas Montarce as executive vice president and chief financial officer (EN, Eli Lilly)
05.09.24	Lilly's QWINT-1, QWINT-3 Phase 3 Studies In Once Weekly Insulin Efsitora Alfa Meet Primary Goals (RTTNews)
05.09.24	In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin (EN, Eli Lilly)
05.09.24	QIAGEN, Lilly To Develop QIAstat-Dx IVD Panel For Early Alzheimer's Disease Risk Identification (RTTNews)
04.09.24	Lilly And EVA Pharma To Expand Access To Baricitinib In Low-to Middle-income Countries In Africa (RTTNews)
04.09.24	Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries (EN, Eli Lilly)
27.08.24	Lilly Releases 2.5 Mg And 5 Mg Vials Of Obesity Drug Zepbound (RTTNews)
27.08.24	Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity (EN, Eli Lilly)
22.08.24	Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference (EN, Eli Lilly)
20.08.24	Eli Lilly: Tirzepatide Lowers Risk Of Developing Type 2 Diabetes By 94% In 3-yr Study (RTTNews)
20.08.24	Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight (EN, Eli Lilly)
16.08.24	Lilly announces retirement of Marschall S. Runge from its Board of Directors (EN, Eli Lilly)
16.08.24	Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (EN, Eli Lilly)
13.08.24	Lilly opens state-of-the-art research and development center in the Boston Seaport (EN, Eli Lilly)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer